Lataa...
A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively
The advent of checkpoint inhibitor therapy in medical oncology has led to an increase in hospitalizations for immune-related adverse effects. Severe colitis has been reported in approximately 5% of patients treated with cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors, such as ipilimu...
Tallennettuna:
| Julkaisussa: | Case Rep Oncol Med |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Hindawi
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6679838/ https://ncbi.nlm.nih.gov/pubmed/31428491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/9069354 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|